NCI-MATCH Treatment Arms Table

NCI-MATCH Searchable Treatment Arms Table

NCI-MATCH is a precision medicine cancer trial with 38 treatment arms. Each arm targets a unique, often rare, gene abnormality known to drive cancer growth. The trial closed to patient enrollment on December 23, 2022. There were a total of 1,201 patients enrolled across all treatment arms.

Below is a searchable list of all treatment arms and their status. Click on the links to access the published trial results. Hover over any of the column headings and click the up/down arrows to sort. You can also search by keyword.

We update this table on an ongoing basis as new publications appear.

GENOMIC TARGET(S) & DRUG(S)	STATUS
ALK translocations - Arm F ROS1 translocations - Arm G Drug: crizotinib Arms F & G	Published
AKT mutations Drug: capivasertib Arm Y	Published
BRAF fusions or non-V600E, non-V600K BRAF mutations Drug: trametinib Arm R	Published
BRAF V600E or BRAF V600K mutations Drugs: dabrafenib + trametinib Arm H	Published
CCND1, 2, and 3 amplifications and Rb protein expression by immunohistochemistry Drug: palbociclib Arm Z1B	Published
CDK4 or CDK6 amplification Drug: palbociclib Arm Z1C	Published
cKIT mutations; PDGFRA or PDGFRB variants and fusions Drug: sunitinib malate Arm V	Published
EGFR-activating mutations Drug: afatinib Arm A	Published
EGFR T790M (with/without an activating mutation) or rare activating mutations of EGFR Drug: osimertinib Arm E	Published
FGFR amplification Drug: erdafitinib Arm K1	Published
FGFR mutations or fusions Drug: erdafitinib Arm K2	Published
FGFR pathway aberrations Drug: AZD4547 Arm W	Published
GNAQ or GNA11 mutations - Arm S2 NF1 mutations - Arm S1 Drug: trametinib Arm S2 and S1	Published
HER2 activating mutations Drug: afatinib Arm B	Published
HER2 amplification Drugs: trastuzumab + pertuzumab Arm J	Published
HER2 amplification Drug: ado-trastuzumab emtansine Arm Q	Published
LAG-3 expression with MMR deficiency Drug: nivolumab Arm Z1D	Published
NF2 loss Drug: defactinib Arm U	Published
NRAS mutations Drug: binimetinib Arm Z1A	Published
PIK3CA mutation with or without PTEN loss Drug: copanlisib Arm Z1F	Published
PIK3CA mutation without RAS mutation or PTEN loss Drug: taselisib Arm I	Published
PTEN loss Drug: copanlisib Arms Z1G and Z1H	Published
AKT mutations Drug: ipatasertib Arm Z1K	Manuscript in progress
BRAF Non-V600 mutations Drug: ulixertinib Arm Z1L	Manuscript in progress
BRCA1 or BRCA2 mutations Drug: adavosertib Arm Z1I	Manuscript in progress
MET amplification - Arm C1 MET exon 14 deletion - Arm C2 Drug: crizotinib Arms C1 & C2	Manuscript in progress
mTOR, KEAP1 or NFE2L2 mutations - Arm L TSC1 or TSC2 mutations - Arm M Drug: sapanisertib Arms L & M	Manuscript in progress
NTRK fusions Drug: larotrectinib Arm Z1E	Manuscript in progress
PTEN loss by immunohistochemistry - Arm P PTEN mutations or deletions, with PTEN expression on immunohistochemistry - Arm N Drug: GSK2636771 Arms: P & N	Manuscript in progress
Smoothened (SMO) or patched 1 (PTCH1) mutations Drug: vismodegib Arm T	Manuscript in progress
DDR2 mutations Drug: dasatinib Arm X	Closed
LAG-3 expression with microsatellite instability (MSI) Drugs: relatlimab + nivolumab Arm Z1M	Closed